---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210310"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:03:03.634888+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neumora Q1 net loss $53.5M, cash $147M; navacaprant data on track for Q2 2026

## Summary
- Net loss of $53.5M for Q1 2026, improved from $68.0M in Q1 2025.
- Cash and cash equivalents $147.1M as of March 31, 2026; expected to fund operations into Q3 2027.
- KOASTAL-2 and -3 fully enrolled with >400 patients each; joint topline readout expected in Q2 2026.
- NMRA-511 Phase 1b showed effect in Alzheimer’s agitation; MAD expansion data in H2 2026, Phase 2 planned Q1 2027.
- NMRA-898 Phase 1 data in stable schizophrenia expected H2 2026; NMRA-215 preclinical update also in H2 2026.

## SEC filing metadata
- accession: 0001193125-26-210310
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312526210310/0001193125-26-210310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312526210310/nmra-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210310
- JSON: https://secwatch.observer/filing/0001193125-26-210310.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210310.txt

## Source-grounded claims
- claim_id: e464bfb2123dbea8bed820afc247ed4f8b5f23f1
  claim: Neumora Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $53.5 million.
  evidence_excerpt: compared to $18.8 million for the same period in 2025. The decrease was primarily attributable to lower personnel-related costs. • Net Loss: The Company reported a net loss of $53.5 million for the first quarter of 2026, as compared to $68.0 million for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312526210310/0001193125-26-210310-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.